TY - JOUR
T1 - Schistosomiasis in the People's Republic of China
T2 - The era of the three Gorges Dam
AU - McManus, Donald P.
AU - Gray, Darren J.
AU - Li, Yuesheng
AU - Feng, Zheng
AU - Williams, Gail M.
AU - Stewart, Donald
AU - Rey-Ladino, Jose
AU - Ross, Allen G.
PY - 2010/4
Y1 - 2010/4
N2 - The potential impact of the Three Gorges Dam (TGD)
on schistosomiasis transmission in China has invoked considerable
global concern. The TGD will result in changes in the water level and
silt deposition downstream, favoring the reproduction of Oncomelania
snails. Combined with blockages of the Yangtze River's tributaries,
these changes will increase the schistosomiasis transmission season
within the marshlands along the middle and lower reaches of the Yangtze
River. The changing schistosome transmission dynamics necessitate a
comprehensive strategy to control schistosomiasis. This review discusses
aspects of the epidemiology and transmission of Schistosoma japonicum
in China and considers the pathology, clinical outcomes, diagnosis,
treatment, immunobiology, and genetics of schistosomiasis japonica
together with an overview of current progress in vaccine development,
all of which will have an impact on future control efforts. The use of
synchronous praziquantel (PZQ) chemotherapy for humans and domestic
animals is only temporarily effective, as schistosome reinfection occurs
rapidly. Drug delivery requires a substantial infrastructure to
regularly cover all parts of an area of endemicity. This makes
chemotherapy expensive and, as compliance is often low, a less than
satisfactory control option. There is increasing disquiet about the
possibility that PZQ-resistant schistosomes will develop. Consequently,
as mathematical modeling predicts, vaccine strategies represent an
essential component in the future control of schistosomiasis in China.
With the inclusion of focal mollusciciding, improvements in sanitation,
and health education into the control scenario, China's target of
reducing the level of schistosome infection to less than 1% by 2015 may
be achievable.
AB - The potential impact of the Three Gorges Dam (TGD)
on schistosomiasis transmission in China has invoked considerable
global concern. The TGD will result in changes in the water level and
silt deposition downstream, favoring the reproduction of Oncomelania
snails. Combined with blockages of the Yangtze River's tributaries,
these changes will increase the schistosomiasis transmission season
within the marshlands along the middle and lower reaches of the Yangtze
River. The changing schistosome transmission dynamics necessitate a
comprehensive strategy to control schistosomiasis. This review discusses
aspects of the epidemiology and transmission of Schistosoma japonicum
in China and considers the pathology, clinical outcomes, diagnosis,
treatment, immunobiology, and genetics of schistosomiasis japonica
together with an overview of current progress in vaccine development,
all of which will have an impact on future control efforts. The use of
synchronous praziquantel (PZQ) chemotherapy for humans and domestic
animals is only temporarily effective, as schistosome reinfection occurs
rapidly. Drug delivery requires a substantial infrastructure to
regularly cover all parts of an area of endemicity. This makes
chemotherapy expensive and, as compliance is often low, a less than
satisfactory control option. There is increasing disquiet about the
possibility that PZQ-resistant schistosomes will develop. Consequently,
as mathematical modeling predicts, vaccine strategies represent an
essential component in the future control of schistosomiasis in China.
With the inclusion of focal mollusciciding, improvements in sanitation,
and health education into the control scenario, China's target of
reducing the level of schistosome infection to less than 1% by 2015 may
be achievable.
UR - http://www.scopus.com/inward/record.url?scp=77950682269&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77950682269&partnerID=8YFLogxK
U2 - 10.1128/CMR.00044-09
DO - 10.1128/CMR.00044-09
M3 - Review article
C2 - 20375361
AN - SCOPUS:77950682269
SN - 0893-8512
VL - 23
SP - 442
EP - 466
JO - Clinical Microbiology Reviews
JF - Clinical Microbiology Reviews
IS - 2
ER -